Global AI in Biotechnology Market to Reach US$1.97 Billion by 2031 at 10.6% CAGR

AI in Biotechnology Market Size

The global market for AI in Biotechnology was valued at US$ 1033 million in the year 2024 and is projected to reach a revised size of US$ 1971 million by 2031, growing at a CAGR of 10.6% during the forecast period.

Get Free Sample Report: https://reports.valuates.com/request/sample/QYRE-Auto-21X19811/Global_AI_in_Biotechnology_Market_Research_Report_2025

Key Highlights

• ML and DL dominate AI adoption in biotechnology due to superior predictive capabilities.
• Drug discovery leads AI use as companies seek faster, more efficient R&D pipelines.
• NLP accelerates literature mining, regulatory analysis, and clinical data interpretation.
• Precision medicine growth drives AI integration across genomics and multi-omics research.
• Asia-Pacific emerges as the fastest-growing region for AI in biotechnology adoption.

By Type
• Machine Learning (ML) & Deep Learning (DL)
• Natural Language Processing (NLP)

By Application
• Drug Discovery & Development
• Genomics & Precision Medicine
• Medical Imaging & Diagnostics

Key Companies
Recursion Pharmaceuticals, Exscientia, XtalPi, Schrödinger, Owkin, Evogene, BioNTech, MedySapiens

Purchase Regional Report: https://reports.valuates.com/request/regional/QYRE-Auto-21X19811/Global_AI_in_Biotechnology_Market_Research_Report_2025

Trends Influencing the Growth of the Global AI in Biotechnology Market

The global AI in biotechnology market is expanding rapidly as life sciences organizations seek to overcome rising research complexity, development costs, and time-to-market pressures. AI technologies are transforming the way biological data is generated, analyzed, and translated into actionable insights, enabling a shift from traditional trial-and-error research models toward predictive, data-driven discovery. As biotechnology companies increasingly adopt computational approaches, AI is becoming a foundational capability across the research and development lifecycle.

From a technology perspective, Machine Learning (ML) and Deep Learning (DL) are emerging as the dominant and fastest-growing segments. These techniques are widely applied in molecular modeling, protein structure prediction, compound screening, and biological pathway analysis. ML and DL models enable researchers to analyze high-dimensional biological datasets, identify complex nonlinear relationships, and generate predictive insights that would be infeasible using conventional statistical methods. Their ability to continuously learn from new data further enhances research accuracy and adaptability. In parallel, Natural Language Processing (NLP) is gaining traction as a critical enabler of knowledge discovery, supporting automated literature mining, clinical trial analysis, and regulatory document processing. NLP tools allow researchers to extract insights from vast volumes of unstructured scientific text, accelerating hypothesis generation and decision-making. The others category, including computer vision and reinforcement learning, also contributes to innovation in areas such as laboratory automation, microscopy analysis, and experimental optimization.

By research direction, Drug Discovery and Development remains the largest and fastest-growing application of AI in biotechnology. AI-driven platforms are transforming early-stage discovery by enabling virtual screening of compound libraries, de novo molecule design, and predictive assessment of drug-target interactions. These capabilities significantly reduce discovery timelines and improve the probability of clinical success by identifying high-quality candidates earlier in the pipeline. AI is also increasingly applied in preclinical testing, biomarker identification, and clinical trial design, enabling better patient stratification, adaptive trial protocols, and real-time monitoring of trial outcomes. This end-to-end integration of AI across the drug development lifecycle is reshaping how biotech companies manage risk, allocate resources, and achieve regulatory approval.

Genomics and precision medicine represent another high-growth research direction, driven by the exponential increase in genomic sequencing data and the growing emphasis on personalized therapies. AI algorithms are essential for interpreting complex genomic variants, identifying disease-associated biomarkers, and predicting patient responses to specific treatments. Machine learning models enable the integration of multi-omics datasets, including genomics, transcriptomics, proteomics, and metabolomics, to generate comprehensive biological insights. This systems-level approach supports the development of targeted therapies, companion diagnostics, and individualized treatment strategies, advancing the shift toward precision healthcare.

Medical imaging and diagnostics are also benefiting significantly from AI adoption in biotechnology. AI-powered computer vision and deep learning models enhance the analysis of histopathology slides, radiology images, and digital biomarkers, enabling faster and more accurate disease detection and classification. These tools support earlier diagnosis, improved prognostic assessment, and better treatment planning, particularly in oncology, neurology, and rare disease research. Integration of imaging AI with genomic and clinical data further strengthens translational research and clinical decision support.

A key trend shaping the AI in biotechnology market is the convergence of AI with high-throughput laboratory automation. Automated laboratories generate massive volumes of experimental data, and AI systems are increasingly used to design experiments, optimize protocols, and interpret results in real time. This closed-loop approach, often referred to as autonomous or self-driving laboratories, accelerates discovery cycles and improves reproducibility, positioning AI as a core component of next-generation research infrastructure.

Another major trend is the increasing availability and interoperability of biological data. Public and private initiatives are expanding access to genomic, proteomic, clinical, and real-world datasets, enabling AI models to be trained on more diverse and representative data. Standardization efforts and data-sharing frameworks further support cross-institutional collaboration, model generalization, and regulatory acceptance of AI-driven insights. Data integration platforms that harmonize structured and unstructured data sources are becoming essential tools for biotech organizations seeking to maximize the value of their data assets.

Regulatory alignment and trust-building are also critical to market growth. Regulatory agencies are developing frameworks for the validation, transparency, and governance of AI-driven tools in biomedical research and clinical applications. Biotechnology companies are increasingly adopting explainable AI models, robust validation protocols, and data governance practices to ensure regulatory compliance and stakeholder confidence. These efforts are essential for the widespread adoption of AI in safety-critical applications such as drug development and diagnostics.

The market is also influenced by the growing role of strategic partnerships and ecosystem collaboration. Biotechnology companies, AI startups, academic institutions, cloud service providers, and pharmaceutical firms are forming alliances to co-develop platforms, share data, and accelerate innovation. These partnerships enable access to complementary expertise, advanced computing infrastructure, and specialized datasets, strengthening competitive positioning and accelerating commercialization.

Finally, the global expansion of AI infrastructure and cloud computing is lowering barriers to entry for biotech organizations of all sizes. Cloud-based AI platforms offer scalable computing resources, pre-trained models, and integrated development environments, enabling rapid experimentation and deployment without significant capital investment. This democratization of AI capabilities is expanding adoption across startups, mid-sized firms, and research institutions, driving sustained market growth.

AI in Biotechnology Market Share

North America currently holds a leading share of the global AI in biotechnology market, supported by strong biotechnology ecosystems, advanced research infrastructure, and early adoption of AI technologies across pharmaceutical and life sciences organizations. Europe represents a significant share, driven by collaborative research initiatives, regulatory alignment, and increasing investment in digital health and precision medicine. Asia-Pacific is expected to experience the fastest market growth, fueled by rapid biotechnology expansion, government-backed AI strategies, and rising investments in genomics, drug discovery, and healthcare innovation.

View Full Report: https://reports.valuates.com/market-reports/QYRE-Auto-21X19811/global-ai-in-biotechnology

Email Id:
Please reach us at sales@valuates.com

Address:
Valuates,
4th Floor,
Balaraj's Arcade,
Whitefield Main road,
Bangalore 560066

Valuates offers an extensive collection of market research reports that helps companies to take intelligent strategical decisions based on current and forecasted Market trends.
To achieve a consistent view of the market, data is gathered from various primary and secondary sources, at each step, data triangulation methodologies are applied to reduce deviance and find a consistent view of the market. Each sample we share contains detail research methodology employed to generate the report, Please also reach to our sales team to get the complete list of our data sources

This release was published on openPR.